A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Recruiting · NCT07489885 · Interventional (participants receive a specific treatment) · Lead sponsor: InventisBio Co., Ltd

Interventions studied

D-2570 TabletPlacebo Tablets

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Age range

18 Years to 70 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 2

Study type

Interventional (participants receive a specific treatment)

Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
Within normal ranges of laboratory assessments

Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

20 locations listed across 11 US states.